Compliance with a Low Molecular Weight Heparin regime in ambulatory orthopedic patients;Współpraca pacjentów ortopedycznych w zakresie ambulatoryjnego stosowania heparyn drobnocza̧steczkowych

Ortopedia Traumatologia Rehabilitacja

Volumn 8, Issue 6, 2006, Pages 633-638

  Karliński, Michał ^a   Stolarczyk, Artur ^a,b   Siuda, Marcin ^a   Ziółkowski, Marcin ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Zaklad Rehabilitacji Klinicznej Oddzialu Fizjoterapii II Wydzialu Lekarskiego AM   (Poland)

Author keywords

Compilance; Low molekular heparins; Patient

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMOBILIZATION; MALE; MEDICAL RESEARCH; PATIENT COMPLIANCE; PATIENT SATISFACTION; POLAND; QUESTIONNAIRE; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

EID: 34248207652     PISSN: 15093492     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Silverstein MD. Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year population-based study. Arch Intern Med 1998; 158 (6): 585-93.
2. Bramlage P, Kirch P, Kirch W. Current concepts for prevention of venous thromboembolism. Eur J Clin Incest 2005; 35 (Suppl. 1): 4-11.
3. Richard H, White MD. The epidemiology of venous thromboembolism. Circulation 2003; 107: 14-18.
4. Cushman M. Incidence rates, case fatality, and recurrence rates of deep vein thrombosis and pulmonary embolus: the Longitudinal Investigation of Thromboembolism Etiology (LITE). Thromb Haemost 2001; 86 (suppl 1): OC2349.
5. Cushman M. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117 (1): 19-25.
6. Heit JA. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86 (1): 452-63.
7. Cohen AT, Alikhan R. Prophylaxis of venous thromboembolism in medical patients. Curr Opin Pulm Med 2001; 7: 332 -7.
8. Mohr DN. The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study. Mayo Clin Proc 2000; 75 (12): 1249-56.
9. Macdougall DA. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 2006 15; 63 (20 Suppl 6): S5-S15.
10. Tilleul P. Estimated annual costs of prophylaxis and treatment of venous thromboembolic events associated with major orthopedic surgery in France. Clin Appl Thromb Hemost 2006; 12 (4): 473-84.
11. Bergqvist D. Low molecular weight heparins. J Intern Med 1996; 240: 63-72.
12. Kakkar H. Compliance with recommended prophylaxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines. J Thromb Haemost 2004; 2: 221-7.
13. Mismetti P. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83 (1): 14-9.
14. Cohen AT. Fondaparinux vs placebo for the prevention of venous thromboembolism in acutely ill medical patients (ARTEMIS). Paper presented at: The XIX Congress of the International Society on Thromb Haemost; July 12-18, 2003; Birmingham, UK. Abstract P2406
15. Leizorovicz A. The assessment of deep vein thromboses for therapeutic trials. Angiology 2003; 54: 19-24.
16. Alikhan R. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003; 14: 341-346.
17. Leizorovicz A, Mismetti P. Preventing Venous Thromboembolism in Medical Patients. Circulation 2004; 110: IV-13 - IV-19.
18. Freedman KB. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty J Bone Joint Surg Am 2000; 82-A (7): 929-38.
19. White RH. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158: 1525-31.
20. Lieberman JR, Hsu WK. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am 2005; 87 (9): 2097-112.
21. William H. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombic and thrombolytic therapy. Chest 2004; 126; 338-400.
22. Zawilska K. Wytyczne profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej. Medycyna Praktyczna 2005; 172 (Suppl.): 16-21.
23. Kujath P, Spannagel U, Habscheid W. Incidence and prophylaxis of deep venous thrombosis in outpatients with injury of the lower limb. Haemostasis 1993; 23 (Suppl): 20-26.
24. Lassen MR, Borris LC, Nakov RL. Use of low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. N Engl J Med 2002; 347: 726-730.
25. Jorgensen PS. Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venographic controlled study. Thromb Res 2002; 105: 477-480.
26. Kock HJ. Thromboprophylaxis with low-molecular-weight heparin in outpatients with plaster cast immobilization of the leg. Lancet 1995; 346: 459-461.
27. Simons MR. Interventions related to compliance. Nurs Clin North Am 1992; 27: 477-494.
28. Charpentier G. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. Diabetes Metab 2005; 31: 189-195.
29. Parris ES. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005; 28 (3): 595-9.
30. Morris LA, Halperin JA. Effects on written drug information on patient knowledge and compliance: A literature review. Am J Public Health 1979; 64: 47-52.
31. Rashid ST. Venous thromboprophylaxis in UK medical inpatients. J R Soc Med 2005; 98: 507-512.
32. Clifford W. Patient compliance with outpatient prophylaxis: an observational study. Orthopedics 2005; 28, 2: 143-7.